Insulin Glargine (insulin Glargine-yfgn recalls
The FDA has published 2 recalls involving Insulin Glargine (insulin Glargine-yfgn since 2022. The latest was reported on 3 Aug 2022. Most were for labeling errors. Recalls usually affect specific lots, not every bottle on the market. Check the lot number on each recall page before acting.
Total recalls2since 2022
Last 12 months0reported
Class I2100% of total
Ongoing0latest 3 Aug 2022
Recalls per month, last 24 months
click a bar for that monthSeverity split
Class I 2 100%Class II 0 0%Class III 0 0%
Why insulin glargine (insulin glargine-yfgn is recalled
Companies
By year
All insulin glargine (insulin glargine-yfgn recalls, newest first
2 total| Reported | Class | Recall | Company | Reason | Where |
|---|---|---|---|---|---|
| Drug | CLASS I | Insulin Glargine (Insulin glargine-yfgn) Injection/mL recalled | Mylan Pharmaceuticals | Labeling Errors | Nationwide |
| Drug | CLASS I | Insulin Glargine (insulin glargine-yfgn) Injection/mL (U-100) recalled | Mylan Pharmaceuticals | Labeling Errors | Nationwide |
Should you stop taking Insulin Glargine (insulin Glargine-yfgn?
Not on your own. Most recalls affect specific lots from one manufacturer, and stopping a prescription suddenly can be riskier than the defect. Check your lot number and NDC against the recall, then call the pharmacy that dispensed it for a replacement.